Navigation Links
Latin American Aortic Stent Graft Market to Reach Over $150 Million by 2015, According to Millennium Research Group
Date:9/23/2010

TORONTO, Sept. 23 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Latin American physicians will increasingly adopt abdominal and thoracic endovascular aortic repair in place of surgical repair through 2015 as awareness of the benefits of endovascular techniques grows and physician training improves.

Thoracic endovascular aortic repair tends to be a slightly more attractive option for physicians and patients because the alternative open surgical procedure is associated with significant mortality, complications, and longer hospital stays. Conversely, newer thoracic aortic stent grafts incorporate features that add to their versatility in treating a variety of thoracic aortic conditions, including aneurysms and dissections. These features include improved deliverability and reliability of stent graft placement, which make it easier for physicians to treat a diverse patient population.  Abdominal endovascular aortic repair, in contrast, will face more competition from surgical options because the latter is not quite as risky in the abdominal aorta compared to in the thoracic aortic. As a result, surgical repair of the abdominal aorta will continue to be preferred in some centers due to the high cost of aortic stent grafts. Although budget constraints among Latin American health care facilities will remain a limiting factor, the aortic stent graft market is set to expand to more than $150 million by 2015.

"Mexico, in particular, has traditionally experienced lower stent graft penetration rates compared to other Latin American countries due to its slow device approval process," says Fareed Hameed, Analyst at MRG.  "Because device approval has lagged behind some other regions, physician training on endovascular repair procedures has also been lower; however, even Mexico will see growth in aortic stent graft procedures of approximately 15% per year through 2015 as manufacturers focus on training individuals in this region."

MRG's Latin American Markets for Peripheral Vascular Devices 2011 report provides critical insight into trends that will fuel market growth for peripheral vascular stents, percutaneous transluminal angioplasty balloon catheters, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts, and peripheral vascular accessory devices.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
6. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Report Details ... Alzheimer,s Disease Therapeutics and Diagnostics ... new study reveals trends, R&D progress, and predicted revenues ... Alzheimer,s disease therapeutics and diagnostics market. Our new report ... How is the Alzheimer,s disease therapeutics and diagnostics market ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... SUNNYVALE, Calif. , Jan. 19, 2017 ... that its CyberKnife® and TomoTherapy® Systems continue to set ... systems received the highest composite overall user satisfaction rating ... to the Q4 2016 MD Buyline Market Intelligence Briefing™. ... achieved the highest composite ratings among industry peers for ...
Breaking Medicine Technology:
(Date:1/20/2017)... , ... January 20, 2017 , ... "TransFlare 4K Mystique ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have ...
(Date:1/20/2017)... ... , ... “The Angel”: a heartwarming and earnest tale of faith and ... children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional ... writer. , When asked of her new book, Marjorie says, “‘The Angel’ was written ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior performance ... RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for Medicare & Medicaid ... CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid ... important part of the Administration’s effort to build a system that delivers better care ...
Breaking Medicine News(10 mins):